Compare FRO & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRO | PTCT |
|---|---|---|
| Founded | 1985 | 1998 |
| Country | Cyprus | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 5.7B |
| IPO Year | 1995 | 2006 |
| Metric | FRO | PTCT |
|---|---|---|
| Price | $37.11 | $68.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 17 |
| Target Price | $37.67 | ★ $80.65 |
| AVG Volume (30 Days) | ★ 2.1M | 1.4M |
| Earning Date | 05-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.85% | N/A |
| EPS Growth | N/A | ★ 264.48 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $264,734,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $17.70 |
| P/E Ratio | $34.05 | ★ N/A |
| Revenue Growth | N/A | ★ 36.19 |
| 52 Week Low | $16.25 | $43.18 |
| 52 Week High | $39.89 | $87.50 |
| Indicator | FRO | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 50.61 | 46.49 |
| Support Level | $36.11 | $62.87 |
| Resistance Level | $39.20 | $69.23 |
| Average True Range (ATR) | 1.33 | 2.81 |
| MACD | -0.10 | -0.18 |
| Stochastic Oscillator | 27.55 | 27.41 |
Frontline PLC is an international shipping company engaged in the seaborne transportation of crude oil and oil products. Group operates through the tankers segment. The tankers segment includes crude oil tankers and product tankers. Its geographical area of operation includes Arabian Gulf, West African, the North Sea, and the Caribbean. Frontline earns revenue through voyage charters, time charters, and a finance lease. It is also involved in the charter, purchase, and sale of vessels.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.